m+Medelevator.RU
← Поиск публикаций
JMIR AI · 2026

Augmenting Large Language Model With Prompt Engineering and Supervised Fine-Tuning in Non-Small Cell Lung Cancer Tumor-Node-Metastasis Staging: Framework Development and Validation.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Jin Ruonan, Ling Chao, Hou Yixuan, Sun Yuhan, Li Ning, Han Jiefei, Sheng Jin, Wang Qizhao, Liu Yuepeng, Zheng Shen, Ren Xingyu, Chen Chiyu, Wang Jue, Li Cheng

Аннотация

BACKGROUND: Accurate tumor node metastasis (TNM) staging is fundamental for treatment planning and prognosis in non-small cell lung cancer (NSCLC). However, its complexity poses significant challenges. Traditional rule-based natural language processing methods are constrained by their reliance on manually crafted rules and are susceptible to inconsistencies in clinical reporting.

OBJECTIVE: This study aimed to develop and validate a robust, accurate, and operationally efficient artificial intelligence framework for the TNM staging of NSCLC by strategically enhancing a large language model, GLM-4-Air (general language model), through advanced prompt engineering and supervised fine-tuning (SFT).

METHODS: We constructed a curated dataset of 492 deidentified real-world medical imaging reports, with TNM staging annotations rigorously validated by senior physicians according to the AJCC (American Joint Committee on Cancer) 8th edition guidelines. The GLM-4-Air model was systematically optimized via a multi-phase process: iterative prompt engineering incorporating chain-of-thought reasoning and domain knowledge injection for all staging tasks, followed by parameter-efficient SFT using low-rank adaptation for the reasoning-intensive primary tumor characteristics (T) and regional lymph node involvement (N) staging tasks. The final hybrid model was evaluated on a completely held-out test set (black-box) and benchmarked against GPT-4o using standard metrics, statistical tests, and a clinical impact analysis of staging errors.

RESULTS: The optimized hybrid GLM-4-Air model demonstrated reliable performance. It achieved higher staging accuracies on the black-box test set: 92% (95% CI 0.850-0.959) for T, 86% (95% CI 0.779-0.915) for N, 92% (95% CI 0.850-0.959) for distant metastasis status (M), and 90% for overall clinical staging; by comparison, GPT-4o attained 87% (95% CI 0.790-0.922), 70% (95% CI 0.604-0.781), 78% (95% CI 0.689-0.850), and 80%, respectively. The model's robustness was further evidenced by its macro-average F1-scores of 0.914 (T), 0.815 (N), and 0.831 (M), consistently surpassing those of GPT-4o (0.836, 0.620, and 0.698). Analysis of confusion matrices confirmed the model's proficiency in identifying critical staging features while effectively minimizing false negatives. Crucially, the clinical impact assessment showed a substantial reduction in severe category I errors, which are defined as misclassifications that could significantly influence subsequent clinical decisions. Our model committed 0 category I errors in M staging and fewer category I errors in T and N staging. Furthermore, the framework demonstrated practical deployability, achieving efficient inference on consumer-grade hardware (eg, 4 RTX 4090 GPUs) with latencies suitable and acceptable for clinical workflows.

CONCLUSIONS: The proposed hybrid framework, integrating structured prompt engineering and applying SFT to reasoning-heavy tasks (T/N), enables the GLM-4-Air model to serve as a highly accurate, clinically reliable, and cost-efficient solution for automated NSCLC TNM staging. This work demonstrates the efficacy and potential of a domain-optimized smaller model compared with an off-the-shelf generalist model, holding promise for enhancing diagnostic standardization in resource-aware health care environments.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты